.jpg "N-Cadherin Cadherin-2 CD325 IHC Mouse Heart (CDH2 1573)")
PDF DatasheetHuman and Mouse Anti-N-Cadherin / Cadherin-2 / CD325 Antibody Product Attributes
N-Cadherin / Cadherin-2 / CD325 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-CDH2 antibody staining is expected to be primarily localized to the cell junctions and plasma membrane.
Observed Antibody Staining Data By Tissue Type:
Variations in N-Cadherin / Cadherin-2 / CD325 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in bile duct cells in the liver, cells in the seminiferous ducts in testis, cells in the tubules in kidney, glandular cells in the adrenal gland and fallopian tube, hepatocytes in liver, myocytes in heart muscle and neuropil in cerebral cortex. More moderate antibody staining intensity was present in bile duct cells in the liver, cells in the seminiferous ducts in testis, cells in the tubules in kidney, glandular cells in the adrenal gland and fallopian tube, hepatocytes in liver, myocytes in heart muscle and neuropil in cerebral cortex. Low, but measureable presence of N-Cadherin / Cadherin-2 / CD325 could be seen in cells in the granular layer in cerebellum, glandular cells in the endometrium, stomach and thyroid gland and islets of Langerhans in pancreas. We were unable to detect N-Cadherin / Cadherin-2 / CD325 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of N-Cadherin / Cadherin-2 / CD325 expression as measured by anti-N-Cadherin / Cadherin-2 / CD325 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | ++ | – | – | + | – | – | +++ | – | – | – | – | – | – | ++ | – | – | + | ++ | – |
| CDH2 Variability | + | ++ | + | + | +++ | + | + | ++ | ++ | + | ++ | ++ | ++ | + | ++ | + | + | +++ | ++ | + |
| N-Cadherin / Cadherin-2 / CD325 General Information | |
|---|---|
| Alternate Names | |
| N-cadherin Cadherin-2, neural cadherin, NCAD, CDH2 | |
| Molecular Weight | |
| 130-140kDa | |
| Chromosomal Location | |
| 18q11.2 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | CDH2 |
| Entrez Gene ID | 1000 |
| Ensemble Gene ID | ENSG00000170558 |
| RefSeq Protein Accession(s) | NP_001783, XP_016881003, XP_011524090, NP_001295105 |
| RefSeq mRNA Accession(s) | NM_001308176, XM_011525788, NM_001792 |
| RefSeq Genomic Accession(s) | NC_000018, NG_011959, NC_018929 |
| UniProt ID(s) | P19022 |
| UniGene ID(s) | Hs464829, Hs606106 |
| HGNC ID(s) | 1759 |
| Cosmic ID(s) | CDH2 |
| KEGG Gene ID(s) | hsa:1000 |
| PharmGKB ID(s) | PA26293 |
| General Description of N-Cadherin / Cadherin-2 / CD325. | |
| Recognizes a protein of ~140kDa, identified as N-Cadherin (NCAD), also known as CD325. N-cadherin is a 140 kDa protein belonging to a family of transmembrane molecules that mediate calcium-dependent intercellular adhesion. Cadherins are involved in controlling morphogenetic movements during development and regulate cell surface adhesion through homotypic adhesion with the same cadherin species. Expression of N-cadherin has been reported on a variety of normal tissues including neuronal, endothelial and muscle cells, and a subpopulation of early hematopoietic progenitor cells. Results aid in the classification of malignant non-carcinomatous neoplasms including mesotheliomas, chordomas, synovial sarcomas, malignant melanomas, epithelioid sarcomas, epithelioid angiosarcomas, clear cell sarcomas as well as serous and endometrioid tumors of the ovary have been demonstrated to be N-cadherin positive, whereas mucinous tumors are negative. Other N-cadherin-positive neoplasms include renal cell carcinomas and some variant breast tumors, including medullary breast carcinomas and sarcomatoid metaplastic breast carcinomas. | |
There are no reviews yet.